Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: TechSci Research | PRODUCT CODE: 1228260

Cover Image

PUBLISHER: TechSci Research | PRODUCT CODE: 1228260

Molnupiravir Market-Global Industry Size, Share, Trends, Opportunity, & Forecast, 2017-2027 Segmented By Application (Influenza, Ebola, COVID-19, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region

PUBLISHED:
PAGES: 117 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 4900
PDF and Excel (Multi-User License)
USD 5900
PDF and Excel (Custom Research License)
USD 8900

Add to Cart

We offer 8 hour analyst time for an additional research. Please contact us for the details.

Global Molnupiravir market may register impressive growth in the forecast period, 2023-2027, due to rising demands for effective pharmaceuticals for the rising cases of COVID-19. The high prevalence of the disease coupled with the viral variant complicates the conditions of the patients and thus leading to severe conditions of the infection and causing death for the population, driving the growth of the global Molnupiravir market in the upcoming five years. Furthermore, increasing research and development activities by various pharmaceutical & biotechnology players for the development of potential antiviral drugs is anticipated to foster market growth.

Molnupiravir is an orally bioavailable form of a potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV2, the causative agent of COVID-19. In simpler terms, the pharmaceutical product Molnupiravir is an orally administered drug that has higher potency as compared to other antiviral drugs against COVID-19. The drug has the chemical composition of mRNA that can act against the viral, and COVID infection-causing virus' RNA. This RNA sequence has an effect against the new SARS-CoV2 too is thus used for controlling the effects of COVID-19.

Rising Instances of COVID-19 Drives Market Growth

Growing instances of COVID-19-positive cases are a major factor driving the growth of the global Molnupiravir market in the upcoming five years. Although through effective vaccinations and the use of precautionary steps, the rapid growth in the cases has been controlled. Although, growing variants of the virus and its evolving effect on the human body affect lives, and thus the demand for efficient pharmaceuticals such as Molnupiravir increases thereby supporting the growth of the global Molnupiravir market in the next five years.

As of 24th May 2022, there are already 528.37 million CVID-19 cases around the world, out of which 85.11 million cases belong to the United States itself. With the viral infection affecting such a large population in the country, the United States government had hastily authorized the administration of Molnupiravir to patients suffering from the mild symptoms of COVID-19. The orally administered capsules had certain concerns and side effects in their early phase-outs. Soon followed by the affordability of the drug as compared to other available treatment drugs, the industry for the drug expanded and with Clinical Phase III human trials already approved, the drug is expected to substantially grow in the forecast years.

Investments & Advancement Wheel In Further Market Growth

Rising investment in the pharmaceutical industry and growing expenses from the consumers toward effective drug development and overcoming the disease drives the growth of the global Molnupiravir market in the upcoming five years. Consumers are eager to adapt to more advanced, highly effective, and efficient drugs. If these drugs are affordable and are available in the local pharmaceutical markets, the distribution channel efficiency further fuels the growth of the global Molnupiravir market in the next five years.

In 2021, more than 3 million courses of Molnupiravir were supplied to the U.S. government within approximately 7 weeks of receiving emergency use authorization from the U.S. food and drug administration. The demands for drugs are high in the North American region looking at the growing instances of the cases in the country. Further evolutions in other pharmaceuticals and advancements in the innovative COVID-19 restricting drugs may create restraint on the growth of the market.

Market Segmentation

The global Molnupiravir market segmentation is based on application, distribution channel, regional distribution, and competitive landscape. Based on application, the market is fragmented into influenza, Ebola, COVID-19, and others. By distribution channel, the market is bifurcated into hospital pharmacies, retail pharmacies, and online pharmacies. The market analysis also studies the regional segmentation, divided among the Asia-Pacific region, North American region, European region, South American region, and Middle East & African region.

Company Profile

Merck Sharp & Dohme Corp., Everest Organics Limited, Optimus Drugs Pvt Ltd., Dr. Reddy's Laboratories Ltd., Cipla Limited, Mylan N.V., Emcure Pharmaceuticals Ltd., Sun Pharmaceutical Industries Limited, Hetero Drugs Ltd., Torrent Pharmaceuticals Ltd., are enlisted in a partial list of major market players of the global Molnupiravir market.

Report Scope

In this report, global Molnupiravir market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Molnupiravir Market, By Type:

  • Influenza
  • Ebola
  • COVID-19
  • Others

Molnupiravir Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Molnupiravir Market, By Region:

  • North America
    • United States
    • Mexico
    • Canada
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Vietnam
    • Philippines
    • Indonesia
    • Malaysia
  • Europe
    • France
    • Germany
    • United Kingdom
    • Spain
    • Italy
    • Denmark
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kenya

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global Molnupiravir market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).
Product Code: 10604

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Molnupiravir Market

4. Executive Summary

5. Voice of Customer

  • 5.1. Factors Contributing to Demand of Molnupiravir
  • 5.2. Choice of Source for Procuring Molnupiravir
  • 5.3. Source of Information
  • 5.4. Barriers to Adoption of Molnupiravir
  • 5.5. Brand Awareness

6. Pharmacodynamic Overview of Molnupiravir

  • 6.1. Mechanism of Action
  • 6.2. Absorption
  • 6.3. Volume of Distribution
  • 6.4. Protein Binding
  • 6.5. Metabolism
  • 6.6. Route of Elimination
  • 6.7. Half Life
  • 6.8. Clearance

7. Clinical Trials

  • 7.1. Ongoing Clinical Trials
  • 7.2. Completed Clinical Trials
  • 7.3. Terminated Clinical Trials
  • 7.4. Clinical Trial Analysis

8. Patent Analysis

  • 8.1. Patent Granted (2017-2021)
  • 8.2. Patent Applications Filed

9. Global Molnupiravir Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value & Volume
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application (Influenza, Ebola, COVID-19, Others)
    • 9.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 9.2.3. By Company (2021)
    • 9.2.4. By Region
  • 9.3. Pricing Analysis
  • 9.4. Product Market Map

10. North America Molnupiravir Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value & Volume
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. Pricing Analysis
  • 10.4. North America: Country Analysis
    • 10.4.1. United States Molnupiravir Market Outlook
      • 10.4.1.1. Market Size & Forecast
        • 10.4.1.1.1. By Value & Volume
      • 10.4.1.2. Market Share & Forecast
        • 10.4.1.2.1. By Application
        • 10.4.1.2.2. By Distribution Channel
    • 10.4.2. Mexico Molnupiravir Market Outlook
      • 10.4.2.1. Market Size & Forecast
        • 10.4.2.1.1. By Value & Volume
      • 10.4.2.2. Market Share & Forecast
        • 10.4.2.2.1. By Application
        • 10.4.2.2.2. By Distribution Channel
    • 10.4.3. Canada Molnupiravir Market Outlook
      • 10.4.3.1. Market Size & Forecast
        • 10.4.3.1.1. By Value & Volume
      • 10.4.3.2. Market Share & Forecast
        • 10.4.3.2.1. By Application
        • 10.4.3.2.2. By Distribution Channel

11. Europe Molnupiravir Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value & Volume
  • 11.2. Market Share & Forecast
    • 11.2.1. By Application
    • 11.2.2. By Distribution Channel
    • 11.2.3. By Country
  • 11.3. Pricing Analysis
  • 11.4. Europe: Country Analysis
    • 11.4.1. France Molnupiravir Market Outlook
      • 11.4.1.1. Market Size & Forecast
        • 11.4.1.1.1. By Value & Volume
      • 11.4.1.2. Market Share & Forecast
        • 11.4.1.2.1. By Application
        • 11.4.1.2.2. By Distribution Channel
    • 11.4.2. Germany Molnupiravir Market Outlook
      • 11.4.2.1. Market Size & Forecast
        • 11.4.2.1.1. By Value & Volume
      • 11.4.2.2. Market Share & Forecast
        • 11.4.2.2.1. By Application
        • 11.4.2.2.2. By Distribution Channel
    • 11.4.3. United Kingdom Molnupiravir Market Outlook
      • 11.4.3.1. Market Size & Forecast
        • 11.4.3.1.1. By Value & Volume
      • 11.4.3.2. Market Share & Forecast
        • 11.4.3.2.1. By Application
        • 11.4.3.2.2. By Distribution Channel
    • 11.4.4. Italy Molnupiravir Market Outlook
      • 11.4.4.1. Market Size & Forecast
        • 11.4.4.1.1. By Value & Volume
      • 11.4.4.2. Market Share & Forecast
        • 11.4.4.2.1. By Application
        • 11.4.4.2.2. By Distribution Channel
    • 11.4.5. Spain Molnupiravir Market Outlook
      • 11.4.5.1. Market Size & Forecast
        • 11.4.5.1.1. By Value & Volume
      • 11.4.5.2. Market Share & Forecast
        • 11.4.5.2.1. By Application
        • 11.4.5.2.2. By Distribution Channel
    • 11.4.6. Denmark Molnupiravir Market Outlook
      • 11.4.6.1. Market Size & Forecast
        • 11.4.6.1.1. By Value & Volume
      • 11.4.6.2. Market Share & Forecast
        • 11.4.6.2.1. By Application
        • 11.4.6.2.2. By Distribution Channel

12. Asia-Pacific Molnupiravir Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value & Volume
  • 12.2. Market Share & Forecast
    • 12.2.1. By Application
    • 12.2.2. By Distribution Channel
    • 12.2.3. By Country
  • 12.3. Pricing Analysis
  • 12.4. Asia-Pacific: Country Analysis
    • 12.4.1. China Molnupiravir Market Outlook
      • 12.4.1.1. Market Size & Forecast
        • 12.4.1.1.1. By Value & Volume
      • 12.4.1.2. Market Share & Forecast
        • 12.4.1.2.1. By Application
        • 12.4.1.2.2. By Distribution Channel
    • 12.4.2. India Molnupiravir Market Outlook
      • 12.4.2.1. Market Size & Forecast
        • 12.4.2.1.1. By Value & Volume
      • 12.4.2.2. Market Share & Forecast
        • 12.4.2.2.1. By Application
        • 12.4.2.2.2. By Distribution Channel
    • 12.4.3. South Korea Molnupiravir Market Outlook
      • 12.4.3.1. Market Size & Forecast
        • 12.4.3.1.1. By Value & Volume
      • 12.4.3.2. Market Share & Forecast
        • 12.4.3.2.1. By Application
        • 12.4.3.2.2. By Distribution Channel
    • 12.4.4. Japan Molnupiravir Market Outlook
      • 12.4.4.1. Market Size & Forecast
        • 12.4.4.1.1. By Value & Volume
      • 12.4.4.2. Market Share & Forecast
        • 12.4.4.2.1. By Application
        • 12.4.4.2.2. By Distribution Channel
    • 12.4.5. Australia Molnupiravir Market Outlook
      • 12.4.5.1. Market Size & Forecast
        • 12.4.5.1.1. By Value & Volume
      • 12.4.5.2. Market Share & Forecast
        • 12.4.5.2.1. By Application
        • 12.4.5.2.2. By Distribution Channel
    • 12.4.6. Vietnam Molnupiravir Market Outlook
      • 12.4.6.1. Market Size & Forecast
        • 12.4.6.1.1. By Value & Volume
      • 12.4.6.2. Market Share & Forecast
        • 12.4.6.2.1. By Application
        • 12.4.6.2.2. By Distribution Channel
    • 12.4.7. Philippines Molnupiravir Market Outlook
      • 12.4.7.1. Market Size & Forecast
        • 12.4.7.1.1. By Value & Volume
      • 12.4.7.2. Market Share & Forecast
        • 12.4.7.2.1. By Application
        • 12.4.7.2.2. By Distribution Channel
    • 12.4.8. Indonesia Molnupiravir Market Outlook
      • 12.4.8.1. Market Size & Forecast
        • 12.4.8.1.1. By Value & Volume
      • 12.4.8.2. Market Share & Forecast
        • 12.4.8.2.1. By Application
        • 12.4.8.2.2. By Distribution Channel
    • 12.4.9. Malaysia Molnupiravir Market Outlook
      • 12.4.9.1. Market Size & Forecast
        • 12.4.9.1.1. By Value & Volume
      • 12.4.9.2. Market Share & Forecast
        • 12.4.9.2.1. By Application
        • 12.4.9.2.2. By Distribution Channel

13. South America Molnupiravir Market Outlook

  • 13.1. Market Size & Forecast
    • 13.1.1. By Value & Volume
  • 13.2. Market Share & Forecast
    • 13.2.1. By Application
    • 13.2.2. By Distribution Channel
    • 13.2.3. By Country
  • 13.3. Pricing Analysis
  • 13.4. South America: Country Analysis
    • 13.4.1. Brazil Molnupiravir Market Outlook
      • 13.4.1.1. Market Size & Forecast
        • 13.4.1.1.1. By Value & Volume
      • 13.4.1.2. Market Share & Forecast
        • 13.4.1.2.1. By Application
        • 13.4.1.2.2. By Distribution Channel
    • 13.4.2. Argentina Molnupiravir Market Outlook
      • 13.4.2.1. Market Size & Forecast
        • 13.4.2.1.1. By Value & Volume
      • 13.4.2.2. Market Share & Forecast
        • 13.4.2.2.1. By Application
        • 13.4.2.2.2. By Distribution Channel
    • 13.4.3. Colombia Molnupiravir Market Outlook
      • 13.4.3.1. Market Size & Forecast
        • 13.4.3.1.1. By Value & Volume
      • 13.4.3.2. Market Share & Forecast
        • 13.4.3.2.1. By Application
        • 13.4.3.2.2. By Distribution Channel

14. Middle East and Africa Molnupiravir Market Outlook

  • 14.1. Market Size & Forecast
    • 14.1.1. By Value & Volume
  • 14.2. Market Share & Forecast
    • 14.2.1. By Application
    • 14.2.2. By Distribution Channel
    • 14.2.3. By Country
  • 14.3. Pricing Analysis
  • 14.4. MEA: Country Analysis
    • 14.4.1. South Africa Molnupiravir Market Outlook
      • 14.4.1.1. Market Size & Forecast
        • 14.4.1.1.1. By Value & Volume
      • 14.4.1.2. Market Share & Forecast
        • 14.4.1.2.1. By Application
        • 14.4.1.2.2. By Distribution Channel
    • 14.4.2. Saudi Arabia Molnupiravir Market Outlook
      • 14.4.2.1. Market Size & Forecast
        • 14.4.2.1.1. By Value & Volume
      • 14.4.2.2. Market Share & Forecast
        • 14.4.2.2.1. By Application
        • 14.4.2.2.2. By Distribution Channel
    • 14.4.3. UAE Molnupiravir Market Outlook
      • 14.4.3.1. Market Size & Forecast
        • 14.4.3.1.1. By Value & Volume
      • 14.4.3.2. Market Share & Forecast
        • 14.4.3.2.1. By Application
        • 14.4.3.2.2. By Distribution Channel
    • 14.4.4. Kenya Molnupiravir Market Outlook
      • 14.4.4.1. Market Size & Forecast
        • 14.4.4.1.1. By Value & Volume
      • 14.4.4.2. Market Share & Forecast
        • 14.4.4.2.1. By Application
        • 14.4.4.2.2. By Distribution Channel

15. Market Dynamics

  • 15.1. Drivers
  • 15.2. Challenges

16. Market Trends & Developments

17. Competitive Landscape

  • 17.1. Company Profiles
    • 17.1.1. Company Details
    • 17.1.2. Financials (As reported)
    • 17.1.3. Key Market Focus and Geographical Presence
    • 17.1.4. Pricing of Target Products
    • 17.1.5. Market positioning
  • 17.2. Merck Sharp & Dohme Corp.
  • 17.3. Everest Organics Limited
  • 17.4. Optimus Drugs Pvt Ltd.
  • 17.5. Dr. Reddy's Laboratories Ltd
  • 17.6. Cipla Limited
  • 17.7. Mylan N.V.
  • 17.8. Emcure Pharmaceuticals Ltd.
  • 17.9. Sun Pharmaceutical Industries Limited
  • 17.10. Hetero Drugs Ltd.
  • 17.11. Torrent Pharmaceuticals Ltd.

18. Strategic Recommendations

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!